AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23452665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy
Number of subjects: 30
Study 23452665 — intervention group
Group type: COMPARATOR
Intervention: Social skills training (active control)
Number of subjects: 30
Study 21387137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure pulsatile lavage
Number of subjects: 79
Study 21387137 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure pulsatile lavage
Number of subjects: 79
Study 19258303 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational orientation intervention combined with Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0
Study 19258303 — intervention group
Group type: COMPARATOR
Intervention: Standard orientation
Number of subjects: 0
Study 17133139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorocarbon polymer film applied to adhesive surface of skin barrier
Number of subjects: 12
Study 17133139 — intervention group
Group type: COMPARATOR
Intervention: Conventional stainless steel plate-based testing method
Number of subjects: 12
Study 15319158 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg
Number of subjects: 414
Study 15319158 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.2 mg
Number of subjects: 414
Study 15319158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (high response)
Number of subjects: 155
Study 11087700 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine treatment (moderate response)
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's assessment of change in disease activity
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Core set measures
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR response criteria
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR improvement criteria
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 155
Study 11087700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient utility (generic health status measure)
Number of subjects: 155
Study 9305476 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema (100 mL suspension, 1 g mesalazine)
Number of subjects: 8
Study 9305476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal foam (1 g mesalazine in 5 mL concentrate, expanding to 40 mL on actuation)
Number of subjects: 8
Study 9305476 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppository (1 g mesalazine)
Number of subjects: 8
Study 8437356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (ETT hooked on the distal end of the stylet at the Murphy eye)
Number of subjects: 108
Study 8437356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (ETT rotated 180 degrees so that the bevel was directed to the right)
Number of subjects: 108
Study 8437356 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (control, ETT attached naturally to the stylet with the bevel facing left)
Number of subjects: 108
Study 3512970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisdiamminedichloro-platinum plus methotrexate)
Number of subjects: 0
Study 3512970 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study 31023842 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 184
Study 28452570 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tool (Surprise Question plus Supportive and Palliative Care Indicators Tool)
Number of subjects: 4365
Study 28452570 — intervention group
Group type: COMPARATOR
Intervention: Unguided intuition
Number of subjects: 4365
Study 27511847 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGIT‐IORT (single-dose intraoperative radiation therapy)
Number of subjects: 0
Study 27511847 — intervention group
Group type: COMPARATOR
Intervention: EBRT (external beam radiation therapy)
Number of subjects: 0
Study 27511847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TARGIT‐IORT and EBRT
Number of subjects: 0
Study 24418248 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein/isoflavone-based meal replacement
Number of subjects: 120
Study 24418248 — intervention group
Group type: COMPARATOR
Intervention: Casein-based meal replacement
Number of subjects: 120
Study 23284643 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (500 µg) and vilanterol (50 µg) combination
Number of subjects: 0
Study 23284643 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium (500 µg) alone
Number of subjects: 0
Study 23284643 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (50 µg) alone
Number of subjects: 0
Study 20192619 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lignocaine patch
Number of subjects: 25
Study 20192619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA
Number of subjects: 25
Study 20192619 — intervention group
Group type: COMPARATOR
Intervention: Electronic dental anesthesia (EDA)
Number of subjects: 25
Study 18184544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sijunzi Decoction (100 ml) administered via nasogastric tube from the second postoperation day to the 9th postoperation day, along with isocaloric and isonitrogonous enteral diet for 8 days
Number of subjects: 59
Study 18184544 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric and isonitrogonous enteral diet started on the second day after operation for 8 days
Number of subjects: 59
Study 18184544 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogonous parenteral diet for 9 days
Number of subjects: 59
Study 15568191 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced gatekeeping procedures
Number of subjects: 0
Study 15568191 — intervention group
Group type: COMPARATOR
Intervention: Parallel gatekeeping procedure
Number of subjects: 0
Study 11547064 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E
Number of subjects: 32400
Study 11547064 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32400
Study 9686462 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern-related suggestions
Number of subjects: 10
Study 9686462 — intervention group
Group type: COMPARATOR
Intervention: Other topic suggestions
Number of subjects: 10
Study 8136110 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (mean dose 32 mg/24 h)
Number of subjects: 36
Study 8136110 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (mean dose 132 mg/24 h)
Number of subjects: 36
Study 2644532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice a day)
Number of subjects: 2644
Study 2644532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2644
Study 1201165 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 104
Study 1201165 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 104
Study 31732522 — intervention group
Group type: COMPARATOR
Intervention: Gene signature (GS) in melanoma training set
Number of subjects: 0
Study 31732522 — intervention group
Group type: COMPARATOR
Intervention: Gene signature (GS) in melanoma test set
Number of subjects: 0
Study 31732522 — intervention group
Group type: COMPARATOR
Intervention: Multivariate Cox model in melanoma test set
Number of subjects: 0
Study 31732522 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1/IFNγ-related genes in NSCLC
Number of subjects: 0
Study 31585686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 27768831 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous once)
Number of subjects: 40
Study 27768831 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg oral weekly for 6 months)
Number of subjects: 40
Study 25936227 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 25936227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 25936227 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 1008
Study 25936227 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study 23850898 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 60 minutes before the procedure.
Number of subjects: 158
Study 23850898 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac sodium rectally at 60 minutes before the procedure and placebo tablets rectally at 6 hours before outpatient hysteroscopy.
Number of subjects: 158
Study 23850898 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 45 to 60 minutes before the procedure.
Number of subjects: 158
Study 21788632 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal treatment group (mobile and web-based self-management patient coaching system)
Number of subjects: 163
Study 21788632 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 163
Study 21788632 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal treatment group
Number of subjects: 163
Study 21788632 — intervention group
Group type: COMPARATOR
Intervention: Maximal treatment group and Usual care
Number of subjects: 163
Study 18586757 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention (brief dialogue with patients)
Number of subjects: 51
Study 18586757 — intervention group
Group type: COMPARATOR
Intervention: Video watching (overview of peripheral arterial disease)
Number of subjects: 51
Study 17013438 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone (20 mg)
Number of subjects: 23
Study 17013438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SLE or UCTD
Number of subjects: 23
Study 17013438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UCTD
Number of subjects: 23
Study 17013438 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 15287932 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 100 mg (one-dose)
Number of subjects: 80
Study 15287932 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for 8 weeks
Number of subjects: 80
Study 15287932 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (one-dose)
Number of subjects: 80
Study 10924631 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with mechanical elevation of the abdominal wall (MEA)
Number of subjects: 31
Study 10924631 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy with CO2 insufflation (CI)
Number of subjects: 31
Study 8612858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin acetate started in the midluteal phase
Number of subjects: 124
Study 8612858 — intervention group
Group type: COMPARATOR
Intervention: Intranasal buserelin acetate started in the early follicular phase
Number of subjects: 124
Study 1611136 — intervention group
Group type: EXPERIMENTAL
Intervention: ponalrestat (600 mg daily)
Number of subjects: 259
Study 1611136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 259
Study 6360414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (6 g four times daily)
Number of subjects: 116
Study 6360414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 31962305 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz local vibration for 10 minutes
Number of subjects: 12
Study 31962305 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 Hz local vibration for 10 minutes
Number of subjects: 12
Study 31962305 — intervention group
Group type: COMPARATOR
Intervention: 0 Hz (sham control) local vibration for 10 minutes
Number of subjects: 12
Study 29751347 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice per day)
Number of subjects: 37
Study 29751347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 28628768 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet delivered Cognitive Behavior Therapy (ICBT) as an add‐on to usual care
Number of subjects: 42
Study 28628768 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) provided at their antenatal clinic
Number of subjects: 42
Study 25740744 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil (25 mL/d for 120 days)
Number of subjects: 127
Study 25740744 — intervention group
Group type: COMPARATOR
Intervention: TAG oil (25 mL/d for 120 days)
Number of subjects: 127
Study 23465817 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring (VR)
Number of subjects: 1297
Study 23465817 — intervention group
Group type: COMPARATOR
Intervention: Progesterone vaginal gel (VG)
Number of subjects: 1297
Study 21925737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 114
Study 21925737 — intervention group
Group type: COMPARATOR
Intervention: Contact lens
Number of subjects: 114
Study 18663631 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and estrogen/progestin hormone therapies (HT)
Number of subjects: 0
Study 18663631 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing hypothesis for hormone therapy
Number of subjects: 0
Study 16807272 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 81
Study 16807272 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation
Number of subjects: 81
Study 14689344 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin therapy
Number of subjects: 2445
Study 14689344 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no therapy
Number of subjects: 2445
Study 10340921 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 16
Study 10340921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8890965 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical and practical session for breast self-examination
Number of subjects: 657
Study 8890965 — intervention group
Group type: COMPARATOR
Intervention: Mailed material for breast self-examination
Number of subjects: 657
Study 1793154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CPM) and high-dose methotrexate (MTX) with coordinated intrathecal therapy (TIT)
Number of subjects: 117
Study 1793154 — intervention group
Group type: COMPARATOR
Intervention: 2 cycles of vincristine plus MTX with leucovorin rescue
Number of subjects: 117
Study 1793154 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of vincristine plus MTX with leucovorin rescue
Number of subjects: 117
Study 6337365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclacillin, administered three times a day for ten days
Number of subjects: 240
Study 6337365 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, administered similarly
Number of subjects: 240
Study 2413646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 161
Study 2413646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 161
Study 2413646 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study 2413646 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 161
Study 29024579 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa 600 mg
Number of subjects: 0
Study 29024579 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa 2000 mg
Number of subjects: 0
Study 29024579 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 0
Study 29024579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27092710 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 322
Study 24257892 — intervention group
Group type: EXPERIMENTAL
Intervention: SLT 2 in the same TM area
Number of subjects: 40
Study 24257892 — intervention group
Group type: COMPARATOR
Intervention: SLT 2 in the upper untreated TM area
Number of subjects: 40
Study 24088091 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 2795
Study 24088091 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 2795
Study 20431391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern positively correlated with meat and alcohol consumption and negatively correlated with fibers, vitamins B9 and C, β-carotene and calcium consumption.
Number of subjects: 1026
Study 20431391 — intervention group
Group type: EXPERIMENTAL
Intervention: Other dietary patterns (not specified)
Number of subjects: 1026
Study 18058838 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 1826
Study 18058838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1826
Study 17310957 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 70
Study 17310957 — intervention group
Group type: COMPARATOR
Intervention: No statin (control)
Number of subjects: 70
Study 12942493 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg per day
Number of subjects: 560
Study 12942493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 10773510 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA)
Number of subjects: 98
Study 10773510 — intervention group
Group type: COMPARATOR
Intervention: Combined peribulbar and retrobulbar block (PRBB)
Number of subjects: 98
Study 8850771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner music (soothing music)
Number of subjects: 5
Study 8850771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner music
Number of subjects: 5
Study 8850771 — intervention group
Group type: COMPARATOR
Intervention: Control period (no music)
Number of subjects: 5
Study 1498266 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac hydrogel bead (HGB) capsule after a standardized breakfast
Number of subjects: 12
Study 1498266 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac hydrogel bead (HGB) capsule under fasted conditions
Number of subjects: 12
Study 6656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Intensity (HI) training at 60-75% HRR (N = 14)
Number of subjects: 32
Study 6656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Intensity (LI) training at 30-45% HRR (N = 14)
Number of subjects: 32
Study 6656559 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising volunteers)
Number of subjects: 32
Study 30865171 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiosity (measured by 7-item Religious Beliefs and Behaviors survey)
Number of subjects: 226
Study 30865171 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-related stigma (measured by Stigma Scale for Chronic Illness)
Number of subjects: 226
Study 28512171 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent PWLs
Number of subjects: 120
Study 28512171 — intervention group
Group type: COMPARATOR
Intervention: Incongruent PWLs
Number of subjects: 120
Study 26116561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) group program
Number of subjects: 128
Study 26116561 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 128
Study 24070367 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01%
Number of subjects: 40
Study 24070367 — intervention group
Group type: COMPARATOR
Intervention: travoprost/timolol
Number of subjects: 40
Study 22033542 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoidal artery ligation followed by ligation and mucopexy (DSL)
Number of subjects: 48
Study 22033542 — intervention group
Group type: COMPARATOR
Intervention: Suture ligation of hemorrhoids (SL)
Number of subjects: 48
Study 20051618 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board exercises for six weeks
Number of subjects: 17
Study 20051618 — intervention group
Group type: COMPARATOR
Intervention: Baseline treatment programs (Control)
Number of subjects: 17
Study 16854948 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials
Number of subjects: 260
Study 16854948 — intervention group
Group type: COMPARATOR
Intervention: Cohort studies
Number of subjects: 260
Study 16854948 — intervention group
Group type: COMPARATOR
Intervention: Case-control studies
Number of subjects: 260
Study 16854948 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 260
Study 16854948 — intervention group
Group type: COMPARATOR
Intervention: Cohort studies and case-control studies
Number of subjects: 260
Study 15505888 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional mixed models adjusting for non-ignorable drop-out
Number of subjects: 0
Study 15505888 — intervention group
Group type: COMPARATOR
Intervention: Maximum likelihood approach assuming ignorable drop-out
Number of subjects: 0
Study 11558858 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan monotherapy (50 to 150 mg)
Number of subjects: 440
Study 11558858 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ (50/0 to 50/12.5 to 100/25 mg)
Number of subjects: 440
Study 11558858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 9755543 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 mg twice a day
Number of subjects: 60
Study 9755543 — intervention group
Group type: COMPARATOR
Intervention: salbutamol 200 mg four times a day
Number of subjects: 60
Study 8071510 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 20
Study 8071510 — intervention group
Group type: COMPARATOR
Intervention: Left lateral decubitus position
Number of subjects: 20
Study 2838318 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8
Study 2838318 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8